Olaf Degen

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6

OBJECTIVE: The objective of the study was to establish whether HIV-1 sub-subtype A6 (HIV-1A6) is a risk factor for virological failure in people with HIV (PWH) treated with the high genetic barrier integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG) or bictegravir (B...